Publications

Antibiotic use in animals. by Phillips I, Casewell M, Cox T, DeGroot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (5): 885

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. by Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM, Piedmonte M and Jones RN published in Clin. Infect. Dis. 2004; 38 (11): 1513-1520

Antimicrobial spectrum and activity of NVP PDF-713, A novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. by Jones RN, Fritsche TR and Sader HS published in Diagn. Microbiol Infect. Dis. 2004; 49 (1): 63-65

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. by Jones RN, Moet GJ, Sader HS and Fritsche TR published in J. Antimicrob. Chemother. 2004; 53 (5): 804-807

Daptomycin activity and spectrum: A worldwide sample of 6,737 clinical Gram-positive organisms. by Streit JM, Jones RN, Sader HS published in J. Antimicrob. Chemother. 2004; 53 (4): 669-674

Letters to the editor: First isolation of bla_VIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. by Mendes RE, Castanheira M, Garcia P, Guzman M, Toleman MA, Walsh TR and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (4): 1433-1434

A pragmatic approach to identify extended-spectrum beta-lactamse-producing Klebsiella pneumoniae in Taiwan: in vitro activity of newer and established antimicrobial agents. by Yu, W-L, Chuang, Y-C, Jones, RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (4): 277-282

Pseudomonas aeruginosa strains harbouring an unusual bla_VIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). by Patzer J, Toleman MA, Deshpande LM, Kaminska W, Dzierzanowska D, Bennett PM, Jones RN and Walsh TR published in J. Antimicrob. Chemother. 2004; 53 (3): 451-456

Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI226), a novel antimicrobial peptide. by Anderegg T.R., Fritsche TR and Jones RN published in J. Clin. Microbiol. 2004; 42 (3): 1386-1387

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. by Streit JM, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 137-143

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 101-105

Antibiotic resistance in hospitalized patients: MYSTIC Program (1999-2002). by Rhomberg PR, Fritsche TR, Sader HS, Jones RN published in Antibiot. Clin. 2003; 7 (Suppl 2): 2-7

Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: Report from the Garenoxacin International Bridging Study. by Jones RN, Gordon KA, Biedenbach DJ published in J. Antimicrob. Chemother. 2004; 53 (2): 258-265

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). by Mutnick AH, Rhomberg PR, Sader HS, Jones RN published in J. Antimicrob. Chemother. 2004; 53 (2): 290-296

Disk diffusion quality control guidelines for NVP PDF-713: A novel peptide deformylase inhibitor. by Anderegg TR, Jones RN, The Quality Control Working Group published in Diagn. Microbiol. Infect. Dis. 2004; 48 (1): 55-57

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. by Jones RN, Streit JM and Fritsche TR published in Int. J. Antimicrob. Agents. 2004; 23 (2): 197-199

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States Medical Centres. by Rhomberg PR, Jones RN, Sader HS and MYSTIC Programme Study Group published in Int. J. Antimicrob. Agents 2004; 23 (1): 52-59

Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. by Anderegg TR and Jones RN published in Int. J. Antimicrob. Agents 2004; 23 (1): 6-10

Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). by Kirby JT, Sader HS, Walsh TR and Jones RN published in J. Clin. Microbiol. 2004; 42 (1): 445-448

Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. by Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (1): 28-52

Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan. by Yu W-L, Wu L-T, Pfaller MA, Winokur PL and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (1): 362-363

bla_VIM-7, an evolutionary distinct metallo-beta-lactamsae gene in a Pseudomonas aeruginosa isolate from the United States. by Toleman MA, Rolston K, Jones RN and Walsh TR published in Antimicrob. Agents Chemother. 2004; 48 (1): 329-332

Are Enterococcus faecalis strains with vat(E) in poultry a reservoir for human streptogramin resistance? vat(E) occurrence in human enterococcal bloodstream infections in North America (SENTRY Antimicrobial Surveillance Program, 2002). by Jones RN, Deshpande LM published in Antimicrob. Agents Chemother. 2004; 48 (1): 360-361

In vitro activities of the novel cephalosporin LB11058 against multidrug-resistant staphylococci and streptococci. by Sader HS, Johnson DM and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (1): 53-62

Dalbavancin (formerly BI397) Activity Against Selected Populations of Antimicrobial-Resistant Gram-Positive Pathogens, Lead author: Jones RN, presented at 41st annual Infectious Diseases Society of America (IDSA), October 9 – 12, 2003, San Diego, CA

Antimicrobial Activity of Daptomycin Against Multi-Drug Resistant Gram-Positive Strains Collected Worldwide, Lead author: Sader HS, presented at 41st annual Infectious Diseases Society of America (IDSA), October 9 – 12, 2003, San Diego, CA

In Vitro Activity of the Novel Des-F(6)-Quinolone, Garenoxacin, Against 27,831 Community Acquired Respiratory Tract Infection (CARTI) Pathogens: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Sader HS, presented at 41st annual Infectious Diseases Society of America (IDSA), October 9 – 12, 2003, San Diego, CA

PK-PD Evaluation of Doripenem Against Extended Spectrum Beta-Lactamase Production Enterobacteraceae, Lead author: Andes DR, presented at 41st annual Infectious Diseases Society of America (IDSA), October 9 – 12, 2003, San Diego, CA

Comparative Activity and Spectrum of Broad-Spectrum Beta-Lactams Tested Against 12,295 Staphylococci and Streptococci: Report from the SENTRY Antimicrobial Surveillance Program (North America: 2001-2002), Lead author: Fritsche TR, presented at 41st annual Infectious Diseases Society of America (IDSA), October 9 – 12, 2003, San Diego, CA

Global Patterns of Susceptibility for 21 Commonly Used Antimicrobial Agents Tested Against 48,440 Enterobacteraceae in the SENTRY Antimicrobial Surveillance Program (1997-2001), Lead author: Sader HS, presented at 41st annual Infectious Diseases Society of America (IDSA), October 9 – 12, 2003, San Diego, CA

Antimicrobial Susceptibility Pattern Comparisons Among Intensive Care Unit (ICU) and General Ward (Non-ICU) Gram-Negative Isolates from the MYSTIC Programme (USA; 1999-2002), Lead author: Rhomberg PR, presented at 41st annual Infectious Diseases Society of America (IDSA), October 9 – 12, 2003, San Diego, CA

Spectrum of Activity for Antimicrobials Tested Against Non-Fermentative Gram-Negative Bacilli (18,569 Strains) Isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001), Lead author: Jones RN, presented at 41st annual Infectious Diseases Society of America (IDSA), October 9 – 12, 2003, San Diego, CA

Recent Declines in Beta-Lactam and MLS_B Resistances Among S. pneumoniae and Age-Related Effects: Report from the SENTRY Antimicrobial Surveillance Program (North America [NA], 1997 – 2002), Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Penicillin and Macrolides Resistance Trends among Streptococcus pneumoniae Isolated in Latin America between 1998 and 2002: Report of SENTRY Antimicrobial Surveillance Program, Lead author: Andrade SS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

In Vitro Activity of Garenoxacin, a Novel Des-F(6)-Quinolone, Against 120,088 Clinical Isolates Collected Worldwide by the SENTRY Antimicrobial Surveillance Program (1999-2002), Lead author: Sader HS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Activity of AZD2563 and Comparator Agents Tested Against 6,444 Staphylococci, Streptococci and Enterococci (North America, 2001 – 2002), Lead author: Fritsche TR, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

In Vitro Activity of the Tigecycline, a New Glycylcycline, Tested against 1,326 Clinical Bacterial Strains Isolated from the Latin American Region, Lead author: Gales AC, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Enhanced Activity of Sitafloxacin against a Large Collection of Gram-positive Isolates From Latin America, Lead author: Andrade SS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

In Vitro Activity of Omiganan (OMI) Pentahydrochloride, a Topical Cationic Peptide, Tested Against Contemporary Bacteria and Yeast Isolates, Lead author: Sader HS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Contemporary In Vitro Synergy Rates for Aztreonam Combined with Newer Fluoroquinolones (FQ) and Beta-Lactams Tested Against Gram-Negative Bacilli, Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Worldwide Assessment of Dalbavancin (BI397) Activity and Spectrum (2002), Lead author: Stephen J, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Doripenem (S-4661), A Novel Carbapenem: Comparative Activity Against Contemporary Pathogens Including Anaerobes, Bactericidal Action and Methods Evaluations, Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Doripenem (S-4661), Antimicrobial Activity Tested Against Drug-Resistant Pathogens, Lead author: Huynh H, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

LB11058, a Novel Cephalosporin, Tested Against Neisseria gonorrhoeae Including Drug-Resistant Pathogens, Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Antimicrobial Activity of LB11058, A Novel Cephalosporin, Tested Against Staphylococci, Streptococci and Enterococci, Lead author: Sader HS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Antimicrobial Activity of LB11058 Tested Against S. pneumoniae, H. influenzae and M. catarrhalis, Lead author: Johnson DM, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Relationship Between Increased Levofloxacin (LEV) Use and Decreased Susceptibility of Streptococcus pneumoniae (SP): Report From the ARREST Program, Lead author: Bhavnani SM, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Risk Assessment of Macrolide Use in Fed Cattle on the Treatment of Human Food-borne Illness, Lead author: Hurd HS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Experience with ESBL-Producing Enterobacteriaceae (ENT) Treated with Carbapenems Compared to Other Beta-Lactams: Outcomes Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

The Emergence of the Extended-Spectrum Beta-Lactamase GES-1 in a Pseudomonas aeruginosa strain in Brazil: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Gales AC, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois